OPTIMIZING PERSONALIZED CARE USING ECONOMIC STUDIES OF GENOMIC TESTING

利用基因组测试的经济学研究优化个性化护理

• 批准号: 9128583
• 负责人: Tracy A Lieu
• 金额: $ 43.05万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-25 至 2018-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9128583
• 关键词: Address; Affect; Back; Breast Cancer gene; Cancer Diagnostics; Cancer Intervention and Surveillance Modeling Network; Cancer Prognosis; Cancer Research Network; Caring; Chronic Disease; Communities; Community Practice; Community of Practice; Cost Effectiveness Analysis; Data; Decision Analysis; Decision Making; Diagnosis; Diagnostic tests; Disease; Economics; Electronics; Emerging Technologies; Evaluation; Family member; Foundations; Future; Gene Expression Profile; Genetic; Genomics; Geographic Locations; Guidelines; Health; Health Benefit; Health Care Costs; Healthcare Systems; Intervention; Investments; Knowledge; Lead; Life; Link; Living Costs; Malignant Neoplasms; Measures; Methods; Modeling; National Cancer Institute; Outcome; Patient Preferences; Patients; Patterns of Care; Physicians; Policies; Population; Prevention; Provider; Public Health; Recommendation; Records; Research; Resources; Risk; Sampling; Structure; Subgroup; Surveys; System; Technology; Testing; Translations; United States National Institutes of Health; Utility Theories; Weight; Work; base; cancer genomics; cancer recurrence; cohort; comparative effectiveness; cost; cost effective; cost effectiveness; data registry; design; economic outcome; effectiveness research; electronic data; health economics; improved; improved outcome; innovation; insight; interest; malignant breast neoplasm; models and simulation; novel; personalized cancer care; personalized care; personalized health care; personalized medicine; prevent; programs; psychologic; public health relevance; research to practice; screening; tool; treatment as usual; tumor

DESCRIPTION (provided by applicant): The challenge of personalized medicine is knowing when and how to apply screening and diagnostic tests and targeted treatments so that they result improved outcomes and cost-effective investment of resources at a population level. To date, genomic tests have been introduced into practice with scant empirical knowledge about their actual impact on health and economic outcomes, or use in diverse patient subgroups by varying physicians in multiple health care systems. No study has estimated the cost-effectiveness of genomic tests as they are used in the community, or used primary data in a robust US population model to compare real-life cost-effectiveness to analyses using trial data or hypothetical cohorts. Our project will use an innovative multi-criteria decision analysis framework to evaluate the impact of physician, patient, and system factors on the prioritization of competing strategies for the delivery of personalized cancer care in the community. We concentrate on cancer because of the large and growing number of genomic applications for this disease, the potential for major public health impact, and our ability to leverage specialized resources based on NCI's investment in several large research programs we lead. Our approaches are designed to be generalizable to personalized health interventions for other chronic diseases. We will (1) Identify critical factors that influence the cost-effectiveness of genomic testing based on guideline- recommended care vs. usual care without genomic testing, using our validated CISNET multi-cohort population model to evaluate an exemplar gene expression profile test in breast cancer; (2) Describe actual community care, and measure criteria important for decisions about use of genomic tests, using existing electronic records linked with registry data from diverse structures of care in two defined geographic regions, and surveys of a nested sample of 800 patients and their physicians; and (3) Test whether population cost-effectiveness based on actual use and outcomes of genomic testing in community practice is different from that predicted assuming all receive guideline care, and evaluate how the use of multi-criteria decision analysis compared with traditional cost-effectiveness analysis affects the prioritization of strategies. This research will provide a generalizable framework and tools for obtaining evidence on factors affecting the cost-effective use of genomic testing in "real world" community practice. Our results will add an important foundation in data and methods for future economic analyses that inform that the translation of NIH-supported research into practice and address priorities to use personalized medicine to better prevent, screen, diagnose, and treat cancer.

描述(由申请人提供)：个性化医疗的挑战是知道何时以及如何应用筛查和诊断测试以及有针对性的治疗，以便在人口层面上改善结果和进行具有成本效益的资源投资。到目前为止，基因组测试被引入到实践中，对其对健康和经济结果的实际影响缺乏经验知识，或者由多个医疗保健系统的不同医生在不同的患者亚群中使用。没有研究估计基因组测试在社区中使用时的成本效益，也没有研究使用强大的美国人口模型中的原始数据来比较现实生活中的成本效益与使用试验数据或假设队列进行的分析。我们的项目将使用创新的多标准决策分析框架来评估医生、患者和系统因素对社区提供个性化癌症护理的竞争战略的优先顺序的影响。我们专注于癌症，是因为这种疾病的基因组应用数量巨大且不断增加，可能对公共健康产生重大影响，以及我们能够利用专门的 资源基于NCI对我们领导的几个大型研究项目的投资。我们的方法被设计成可推广到针对其他慢性病的个性化健康干预。我们将(1)确定影响基于指南推荐的护理与没有基因组测试的常规护理的基因组测试的成本效益的关键因素，使用我们验证的CISNET多队列人群模型来评估乳腺癌样本基因表达谱测试；(2)描述实际的社区护理，并使用现有的电子记录和来自两个定义的地理区域的不同护理结构的注册数据相链接的现有电子记录，以及对800名患者及其医生的嵌套样本的调查，来描述实际的社区护理，并测量对关于使用基因组测试的决定的重要标准；以及(3)检验基于社区实践中基因组检测的实际使用和结果的人口成本效益是否与假设所有人都接受指南护理的预测结果不同，并评估与传统成本效益分析相比，多标准决策分析的使用如何影响战略的优先顺序。这项研究将提供一个可推广的框架和工具，以获得关于影响在“现实世界”社区实践中经济有效地使用基因组测试的因素的证据。我们的结果将为未来的经济分析增加重要的数据和方法基础，告知NIH支持的研究转化为实践，并解决使用个性化药物更好地预防、筛查、诊断和治疗癌症的优先事项。